Elomatic takes lead in FinVector’s new pharmaceutical plant project
The production of bladder cancer medications is expanding in Kuopio, Finland, as pharmaceutical company FinVector launches the construction of its new GMP6 facility, aiming to improve global access to these treatments. Chosen as a key partner, Elomatic will support FinVector with comprehensive project management, serving in a central advisory role.
Elomatic and FinVector signed an EPCM agreement on May 6, 2025. Under the agreement, Elomatic is responsible for the engineering, procurement, and construction management of the new GMP6 facility. The plant will manufacture the same viral vector drugs for bladder cancer as the GMP5 facility, for which Elomatic also served as the project management consultant during 2023–2024.
“Elomatic was a natural choice as a partner for this project. In addition to the GMP5 facility project, we have decades of successful collaboration with them, and we have strong confidence in their expertise,” says Tony Lönnbäck, Capital Project Director at FinVector.
The construction work will take place in the same building as the GMP5 facility. However, GMP6 is not merely a copy of its predecessor – its processes have been further developed to meet evolving production needs. Design work began at the end of 2023, and installation of the production areas will take place during 2025. The facility is scheduled to be commissioned in early 2026, followed by a validation phase.
The design of the facility has focused not only on strict cleanliness and safety requirements but also on sustainability principles such as energy efficiency. Elomatic’s team includes a wide range of experts, from project management and design to procurement and quality.
“It is a great privilege to continue our collaboration with FinVector on such an impactful project. Being entrusted with the lead responsibility for the GMP6 facility is a significant vote of confidence and reinforces our position as a trusted partner in demanding facility projects,” says Mona Åkerholm, who leads Elomatic’s Pharma unit.
FinVector’s investment strengthens regional vitality and promotes Finland’s position among the leading countries in biotechnology and pharmaceuticals. The company’s multicultural work community already includes experts from over 50 different countries.
Further information:
Mona Åkerholm, Senior Vice President, Elomatic
p. +358 50 477 2871
mona.akerholm@elomatic.com
Elomatic is an international consulting and engineering company that provides top-level expert services, products and turnkey solutions to process, machinery, marine, energy and pharmaceutical industries. We are focused on continuous improvement and sustainable development, and we are committed to design solutions that increase the wellbeing of people and the environment. Established in 1970, Elomatic employs over 1,200 professionals, and has customers in more than 80 countries across the globe.
FinVector Oy, part of the Ferring Ventures Group based in Kuopio, Finland, is the world’s leading research and product developer and manufacturer of viral-based gene therapy products. Founded in Kuopio in 1993, the company currently operates four independent operation suites. It is building a fifth production suite in a greenfield manufacturing plant close to its facilities.